SG188529A1 - A sanguisorba tannin extract, and preparation method and use thereof - Google Patents
A sanguisorba tannin extract, and preparation method and use thereof Download PDFInfo
- Publication number
- SG188529A1 SG188529A1 SG2013018692A SG2013018692A SG188529A1 SG 188529 A1 SG188529 A1 SG 188529A1 SG 2013018692 A SG2013018692 A SG 2013018692A SG 2013018692 A SG2013018692 A SG 2013018692A SG 188529 A1 SG188529 A1 SG 188529A1
- Authority
- SG
- Singapore
- Prior art keywords
- tannins
- extract
- sanguisorba
- ethanol
- bone marrow
- Prior art date
Links
- 229920001864 tannin Polymers 0.000 title claims abstract description 276
- 235000018553 tannin Nutrition 0.000 title claims abstract description 276
- 239000001648 tannin Substances 0.000 title claims abstract description 276
- 244000173853 Sanguisorba officinalis Species 0.000 title claims abstract description 275
- 235000008282 Sanguisorba officinalis Nutrition 0.000 title claims abstract description 275
- 239000000284 extract Substances 0.000 title claims abstract description 171
- 238000000605 extraction Methods 0.000 title claims description 26
- 238000002360 preparation method Methods 0.000 title description 33
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 69
- 150000007949 saponins Chemical class 0.000 claims abstract description 54
- 229930182490 saponin Natural products 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 49
- 230000005764 inhibitory process Effects 0.000 claims abstract description 49
- 229930190125 Sanguisorbin Natural products 0.000 claims abstract description 29
- 238000001959 radiotherapy Methods 0.000 claims abstract description 24
- 238000002512 chemotherapy Methods 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 150
- 239000000243 solution Substances 0.000 claims description 118
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 75
- 239000011347 resin Substances 0.000 claims description 74
- 229920005989 resin Polymers 0.000 claims description 74
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 50
- 235000017709 saponins Nutrition 0.000 claims description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- 238000001179 sorption measurement Methods 0.000 claims description 45
- 235000005487 catechin Nutrition 0.000 claims description 37
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 36
- 229920002350 Procyanidin B2 Polymers 0.000 claims description 36
- XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 claims description 36
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 35
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 35
- 229950001002 cianidanol Drugs 0.000 claims description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 31
- 201000002364 leukopenia Diseases 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 210000002798 bone marrow cell Anatomy 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims description 18
- 238000004587 chromatography analysis Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000006920 protein precipitation Effects 0.000 claims description 8
- 206010043554 thrombocytopenia Diseases 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 241000220222 Rosaceae Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 235000004789 Rosa xanthina Nutrition 0.000 claims description 2
- 244000284152 Carapichea ipecacuanha Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 25
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 45
- 210000000265 leukocyte Anatomy 0.000 description 42
- 238000002474 experimental method Methods 0.000 description 36
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 35
- 238000012360 testing method Methods 0.000 description 33
- 239000000126 substance Substances 0.000 description 28
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 27
- 229960004397 cyclophosphamide Drugs 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- 239000012488 sample solution Substances 0.000 description 25
- 238000001647 drug administration Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 210000000601 blood cell Anatomy 0.000 description 21
- 210000001772 blood platelet Anatomy 0.000 description 21
- 210000003743 erythrocyte Anatomy 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000007423 decrease Effects 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 13
- 108010054147 Hemoglobins Proteins 0.000 description 13
- 239000003480 eluent Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 229940074391 gallic acid Drugs 0.000 description 12
- 235000004515 gallic acid Nutrition 0.000 description 12
- 238000010171 animal model Methods 0.000 description 11
- 150000002989 phenols Chemical class 0.000 description 11
- 238000012449 Kunming mouse Methods 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 230000004526 pharmaceutical effect Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 238000000528 statistical test Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 8
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 6
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 6
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 235000012734 epicatechin Nutrition 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 4
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 4
- 206010015287 Erythropenia Diseases 0.000 description 4
- 229920001991 Proanthocyanidin Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004821 effect on bone Effects 0.000 description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- 125000004403 catechin group Chemical group 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002881 effect on leukopenia Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000013386 optimize process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 241000661154 Eosamon Species 0.000 description 1
- 241001307210 Pene Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000000788 granulopoietic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
AbstractA tannin extract of Sanguisorba officinalis L. contains tannin in a range of 35%-100% (w/w), wherein the content of total saponin is less than 10% (w/w), and the content of sanguisorbin I is less than 5% (w/w). The extract can protect bone marrow hematopoietic stem cells, relieve the inhibition of mouse bone marrow DNA caused by drugs for radiotherapy and chemotherapy, as well as increase numbers of leucocytes.
Description
A sanguisorba tannins extract, and preparation method and use thereof
The present invention belongs to pharmaceutical field, and relates to a sanguisorba tannins extract, and preparation method and use thereof.
Bone marrow inhibition refers to the decrease of activity of blood cell precursor in bone marrow. Both white cells and red cells in blood originate from hemopoietic stem cells in bone marrow. Blood cells in blood always need to be continually replenished due to their short life. In order to achieve the purpose of timely supplements, stem cells as the precursor of blood cells must rapidly divide.
Chemotherapy, radiotherapy and various other antitumor therapies are directed to rapidly dividing cells, which always result in the inhibition of normal bone marrow cells, causing bone marrow hematopoiesis functional disturbance of patients, and further decreasing red cells, white cells and platelets ofpatients, thus leading to the phenomena such as anemia, bleeding and declining in immune function.
Leucopenia is a common hematological disorder, and means a situation of white cells in peripheral blood continuously less than 4*10%/L. White cells are used for defending bacteria. With white cells decreasing, antibacterial ability in the body will be weakened, thus enabling people easily vulnerable. Especially, immunosuppressant used in radiotherapy, chemotherapy, infected, rheumatism, systemic lupus erythematosus and anti-TB drug rifampicin used in infectious diseases can all result in the decrease of white cells in peripheral blood, thus weakening antibacterial ability in the body and causing side effects such as poor immune function. Currently, leucopenia mainly comprises two types, i.c., unexplained leucopenia and secondary leucopenia. The former is common, while the latter is always caused by bone marrow injury which may be the result of radiotherapy, chemotherapy, infection, immune factors, etc.
Although leucopenia and bone marrow inhibition both present a significant phenomenon of white cells decrease, they also have some differences in utilizing of drugs. Currently, some drugs with the function of increasing white cells have no function of protecting bone marrow. For example, rhG-CSF has a strong effect on increasing white cells, but a non-ignored negative influence on bone marrow cells.
Hence, it is necessary to find out a drug which can increase white cells concentrations and as well effectively protect bone marrow cells.
Sanguisorba originates from the dried roots of Rosaceae plants, Sanguisorba officinalis L. or Sanguisorba officinalis L. varlongifolia (Bert.) Yu et Li, with the functions of cooling blood and hemostasis, detoxification and sore healing. Garden
Burnet Root (scientific name: Radix Sanguisorbae) comprises a large amount of tannins (about 20%), and further comprises compounds such as saponins and flavones.
Currently, most researches focus on Sanguisorba focus on Sanguisorba saponins. It is generally believed that Sanguisorba saponins are active ingredients in Sanguisorba to increase white cells and protect bone marrow. Domestic fundamental research on
Sanguisorba increasing white cells believed that Sanguisorba saponins are main activity parts to enhance the proliferation in vitro of bone marrow cells of mice; moreover, Sanguisorba saponins also can increase the numbers of white cells, red cells and platelets of bone marrow inhibition of mice. However, Sanguisorba tannins and Sanguisorba flavones can’t promote bone marrow cells proliferation, instead cause bone marrow inhibition in high concentrations. (Gao Xiaoping ef al. Screen of active parts for Sanguisorba hematopoietic function, Chinese Journal of Natural
Medicines, Volume 4(2), 2006).
Currently, researches on efficacy of sanguisorba tannins are relatively rare. It is reported in foreign literatures that sanguisorba tannins have anti-cancer functions [Bastow kF. Bort LD. Fukushrma Y er al. Inhibition of DNA topoisomerases by sanguim H-6, a cytotoxic dimeric ella-gitan-ton from sanguisorba officinalis. Planta
Med, 1993;59(3):240-245.]. There are some reports about the sanguisorba tannins extract, for example, sanguisorba tannins extract containing 43.86% tannins is obtained through extraction with 70% hydrous acetone (Gao Xiaoping et al. Chinese
Journal of Natural Medicines, Volume 4(2), 2006). Extracted by using acetone but without separation, the sanguisorba tannins extract obtained by the above process not only contains tannins, but also contains saponins, which comprises 15% saponins by detection. Wang Manli ef al. separated sanguisorba tannins from sanguisorba saponins by using an aluminium oxide column, and can finally achieve the separation (Journal of Guizhou Institute of Technology, Volume 22(2), 1993).
As yet, no report related to applying sanguisorba tannins into bone marrow protection and leucopenia therapy has been known.
The present invention aims to provide a sanguisorba tannins extract, and further aims to provide new uses of said sanguisorba tannins extract and compounds contained in Sanguisorba tannins.
The present invention provides a sanguisorba tannins extract, wherein said extract comprises 35%-100%(w/w) of tannins, less than 10% (w/w) of total saponins, and less than 5% (w/w) of sanguisorbin I.
Preferably, said extract contains 50%-100% (w/w) of tannins, more preferably 55%-100% (w/w) of tannins.
Preferably, said extract comprises less than 7.2% (w/w) of total saponins, and less than 4.9% (w/w) of sanguisorbin I. Preferably, said extract comprises less than 0.001% (w/w) of total saponins, and less than 0.0001% (w/w) of sanguisorbin I.
Further, sanguisorba tannins comprise 0.05% to 3.0% by weight of sanguiin, 1.0% to 5.0% by weight of catechin, and 0.05% to 1.5% by weight of proanthocyanidin B2, all calculated based on said extract. Further preferably, said sanguisorba tannins comprise 1.0% to 2.0% by weight of sanguiin, 2.0% to 4.0% by weight of catechin, and 0.05% to 0.4% by weight of proanthocyanidin B2, all calculated based on said extract.
Further, said extract contains 62%-100% (w/w) of tannins.
Said extract originates from dried roots of Sanguisorba officinalis L or
Sanguisorba officinalis L. var.longifolia (Bert.) Yu et Li of Rosaceae.
Said extract can be prepared by the following steps: 1) extraction: grinding Garden Burnet Root (scientific name: Radix
Sanguisorbae) into coarse powders, extracting it with water, alcohol, hydrous ethanol, acetone or hydrous acetone, and obtaining a concentrated solution after filtration and concentration;
2) purification: treating the concentrated solution obtained in step 1) with common tannins separation method, thus obtaining the sanguisorba tannins extract.
Said common tannins separation method comprises chromatography method, protein precipitation method, solvent method or the combination thereof.
Further, said chromatography method is adsorption chromatography. Preferably in said chromatography method the absorption is carried out with gel and macro- porous adsorption resin.
Further, in said protein precipitation method the precipitation is carried out with gelatin.
Further, in said solvent method, aqueous solution containing the concentrated solution is defatted and then extracted by ethyl acetate so as to obtain the sanguisorba tannins extract; alternatively, the concentrated solution is dissolved in ethanol and ethyl acetate, and the extract is precipitated through adding ethyl ether or petroleum ether.
Moreover, said extract is prepared by the following steps: 1) extraction: grinding Garden Burnet Root (scientific name:Radix Sanguisorbae) into coarse powders, extracting it with water, alcohol, 10%-90% hydrous ethanol, acetone or 50%-90% hydrous acetone, and obtaining a concentrated solution after filtration and concentration; 2) purification: adsorbing and purifying the concentrated solution with macroporous adsorption resin, wherein it is eluted with water into colorless, then with 10% ethanol, finally with 60% ethanol, and collecting the elution with 60% ethanol, thus obtaining the sanguisorba tannins extract after drying; alternatively, defatting the concentrated solution and then extracting it with ethyl acetate, thus obtaining the sanguisorba tannins extract.
Preferably, the concentration of said hydrous ethanol is 70%; the concentration of said hydrous acetone is 70%.
Said macroporous adsorption resin is non-polarity resin or low-polarity resin.
Preferably, said macroporous adsorption resin is DA-201 macroporous adsorption resin, D-101 macroporous adsorption resin, LSA-20 macroporous adsorption resin,
HP-10 macroporous adsorption resin or AB-8 macroporous adsorption resin.
The present invention also provides a process for preparing said sanguisorba tannins extract, the process comprising: 1) extraction: grinding Garden Burnet Root (scientific name:Radix Sanguisorbae) into coarse powders, extracting it with water, alcohol, hydrous ethanol, acetone or hydrous acetone, and obtaining a concentrated solution after filtration and concentration ; 2) purification: treating the concentrated solution with common tannins separation method, thus obtaining the sanguisorba tannins extract.
Said common tannins separation method comprises chromatography method, protein precipitation method, solvent method or the combination thereof.
Further, said chromatography method is adsorption chromatography, preferably in said chromatography method the absorption is carried out with gel and macro- porous adsorption resin.
Further, in said protein precipitation method the precipitation is carried out with gelatin.
Further, in said solvent method, aqueous solution containing the concentrated solution is defatted and then extracted by ethyl acetate so as to obtain the sanguisorba tannins extract; alternatively, the concentrated solution is dissolved in ethanol and ethyl acetate, and the extract is precipitated through adding ethyl ether or petroleum ether.
Moreover, said extract is prepared by the following steps: 1) extraction: grinding Garden Burnet Root (scientific name:Radix Sanguisorbae) into coarse powders, extracting it with water, alcohol, 10%-90% hydrous ethanol, acetone or 50%-90% hydrous acetone, and obtaining a concentrated solution after filtration and concentration; 2) purification: adsorbing and purifying the concentrated solution with macroporous adsorption resin, wherein it is eluted with water into colorless, then with 10% ethanol, finally with 60% ethanol, and collecting the elution with 60% ethanol, thus obtaining the sanguisorba tannins extract after drying; alternatively, defatting the concentrated solution and then extracting it with ethyl acetate, thus obtaining the sanguisorba tannins extract.
Preferably, the concentration of said hydrous ethanol is 70%; the concentration of said hydrous acetone is 70%.
Said macroporous adsorption resin belongs to non-polarity resin or low-polarity resin. Preferably, said macroporous adsorption resin is DA-201 macroporous adsorption resin, D-101 macroporous adsorption resin, LSA-20 macroporous adsorption resin, HP-10 macroporous adsorption resin or AB-8 macroporous adsorption resin.
The present invention also provides the use of said sanguisorba tannins extract for manufacturing medicaments for protecting bone marrow.
Said medicaments are used to prevent or/and treat bone marrow inhibition.
Further, said medicaments are used to prevent or/and treat normal bone marrow cells inhibition caused by radiotherapy or chemotherapy.
Moreover, said medicaments are used to prevent or/and treat anemia, leucopenia, or thrombocytopenia caused by radiotherapy or chemotherapy, preferably to prevent or/and treat leucopenia, caused by radiotherapy or chemotherapy.
The present invention further provides the use of said sanguisorba tannins extract for manufacturing medicaments for the treatment of leucopenia.
The present invention further provides the use of sanguiin and proanthocyanidin
B2 for manufacturing medicaments for protecting bone marrow.
Said medicaments are used to prevent or/and treat bone marrow inhibition.
Further, said medicaments are used to prevent or/and treat normal bone marrow cells inhibition caused by radiotherapy or chemotherapy.
Moreover, said medicaments are used to prevent or/and treat anemia, leucopenia, or thrombocytopenia caused by radiotherapy or chemotherapy, preferably to prevent or/and treat leucopenia, caused by radiotherapy or chemotherapy.
The present invention further provides the use of sanguiin, proanthocyanidin B2 for manufacturing medicaments for the treatment of leucopenia.
The present invention also provides a medicinal composition for preventing or treating bone marrow inhibition, leucopenia, comprises an effective amount of sanguiin, proanthocyanidin B2 or said sanguisorba tannins extract as active ingredients, and is prepared to common formulation by adding pharmaceutically acceptable supplementary materials or assisted ingredients.
Said formulation is an oral formulation.
The present invention further provides the use of tumor chemotherapeutics and said sanguisorba tannins extract for manufacturing medicaments for the combination treatment of anti-tumor.
Said tumor chemotherapeutics are alkylating agent.
Further, said tumor chemotherapeutics are cyclophosphamides.
The present invention also provides a medicinal composition for anti-tumor, wherein it is an formulation prepared from an effective amount of tumor chemotherapeutics, the sanguisorba tannins extract according to any one of claims 1- 16 as active ingredient, and pharmaceutically acceptable adjuvant.
Said tumor chemotherapeutics are alkylating agent.
Further, said tumor chemotherapeutics are cyclophosphamides.
The active ingredient in the sanguisorba tannins extract according to the present invention is sanguisorba tannins, which can protect bone marrow hematopoietic stem cells, have remarkable protective effects on the inhibition of mouse bone marrow
DNA caused by chemical substances and radiotherapy, thus providing a new choice for relieving inhibition of normal bone marrow cells caused by radiotherapy and chemotherapy. In addition, sanguisorba tannins can also effectively increase white cells. The sanguisorba tannins extract according to the present invention, when used in combination with chemotherapeutics, can not only improve the curative effect of anti-tumor, but protect bone marrow cells and whole blood cells, reduce or avoid the damages to bone marrow cells and whole blood cells caused by chemotherapeutics.
Therefore, before, after, or during the treatment of cancer with radiotherapy or chemotherapy, the sanguisorba tannins extract according to the present invention can be used in combination with radiotherapy and chemotherapeutics, in order to reduce or avoid the injury to bone marrow cells and white cells of patients caused by radiotherapy or chemotherapy.
Specific Embodiments of the Invention 1. Measurement of the content of Sanguisorba tannins in the present invention.
The content of tannins is measured according to Appendix XB of Chinese
Pharmacopoeia (Edition 2010, Volume I).
The experiment should be performed away from light.
Preparation of reference solutions. 50 mg of gallic acid as control substance is weighed out accurately and added into a 100ml brown volumetric flask. Water is added to dissolve the gallic acid and dilute it until the solution reaches the graduation line. 5Sml of the solution is weighed out accurately and placed into a 50ml brown volumetric flask. Water is added to dilute the solution until it reaches the graduation line. The solution is then shaken well, thus obtaining the control solution with 0.05 mg gallic acid per 1 ml solution.
Preparation of standard curve. 0.5ml, 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml of control solutions are weighed out accurately and added into six 25ml brown volumetric flasks respectively. 1ml of phosphomolybdium tungstic acid solution is added to each of the above flasks, and then 11.50ml, 11ml, 10ml, 9ml, 8ml and 7ml of water are added therein respectively. Each solution is diluted with 29% sodium carbonate solution to reach the graduation line and shaken well. After the solution is stood for 30 min, the absorbency at a wavelength of 760nm is determined according to UV-VIS spectrophotometry (Appendix VA) with the corresponding reagent as the blank test. Then, the standard curve can be obtained with the absorbency as Y-axis against the concentration as X-axis.
Preparation of sample solutions. 0.1g of extract powders are weighed out accurately and added into a 250-ml brown volumetric flask. 150ml of water is added in the flask. The solution is stood for night and then treated by ultrasonic for 10 min.
After being cooled, it is diluted with water to reach the graduation line. The solution is shaken well and stood so as to enable solids to be precipitated from the solution.
The solution is filtered and 50ml of preliminary filtrate is abandoned, whereas 20ml of residual filtrate is weighed out accurately and then transferred into a 100ml brown volumetric flask. Then, the obtained solution is diluted with water to reach the graduation line and shaken well, thus obtaining the sample solution.
Measurement
Total phenols. 2ml of sample solution is weighed out accurately and added into a 25ml brown volumetric flask. According to the method provided in the part of “preparation of standard curve”, after “Iml of phosphomolybdium tungstic acid solution is added”, 10ml of water is added. The absorbancy is determined in a conventional manner, and the weight (mg) of gallic acid in the sample solution can be read out from the standard curve. Thus the content of total phenols can be obtained by calculation.
Non-adsorbed polyphenols. 25ml of sample solution is weighed out accurately and then added to a 100ml conical flask filled with 0.6g of casein. The flask is sealed with a cover and placed in a water bath with a temperature of 30°C for 1h. The flask is constantly shaken, and then removed from the water bath and cooled. The solution is shaken well and filtered, and the preliminary filtration is abandoned. 2ml of residual filtration is weighed out accurately, and then transferred into a 25ml brown volumetric flask. According to the method provided in the part of “preparation of standard curve”, after “Iml of phosphomolybdium tungstic acid solution is added”, 10ml of water is added. The absorbancy is determined in a conventional manner, and the weight (mg) of gallic acid in the sample solution can be read out from the standard curve. Thus the content of the non-adsorbed phenols can be obtained by calculation.
The content of tannins is calculated based on the following formula: the amount of tannins = the amount of total phenols — the amount of non-adsorbed polyphenols. 2. Method for measuring the content of sanguiin, catechin and proanthocyanidin
B2
See, LIU Haiying, Component analysis and Function research on Sanguisorba polyphenols, Shaanxi Normal University, 2009. Details are as follows. 2.1 Instruments and Experimental materials 2.1.1 Instruments
Agilent 1200 high performance liquid chromatography (Agilent 1200 diode array detector; Quaternary pump online degassing systems; Agilent 1200 chromatography workstation) (Agilent Technologies);
Mettler AE240 one over hundred-thousand electronic analytical balance (Mettler,
Germany);
FA1104 one over ten-thousand electronic analytical balance (Shanghai analytical balance Electronic Instrument Co., Ltd.);
KQ3200-type ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd) 2.1.2 Reagent
Proanthocyanidin B2 (Purity: at least 99% by HPLC)
Catechin (Purity: at least 99% by HPLC)
Sanguiin (Purity: at least 99% by HPLC)
Methanol is HPLC grade;
Water produced by redistilling (self-made);
All other reagents used herein are analytical grade. 2.1.3 Sanguisorba tannins extract
The sanguisorba tannins extract is prepared according to the following examples. 2.2 Preparation of sample solution
Ig of sanguisorba tannins extract is weighed out accurately, and transferred to a 100ml volumetric flask. 90ml of water is added, and the solution is treated by ultrasonic for 30min (with 250W of power and 20KHz of frequency rate). After treatment, the solution is cooled and diluted with water to reach the graduation line, and then filtered. 2.3 Chromatography conditions 2.3.1 The selection of detection wavelength
In order to maximize information from the chromatogram and display the whole components of sanguisorba as many as possible, the components should be generally separated from each other using binary gradient elution of methanol-phosphate buffered saline at a column temperature of 30°C. All the chromatogram-spectrum information having chromatogram components falling into the spectrum region at the range of 195nm-400nm are collected with a diode array detector (DAD). Based on the absorption status of peaks in the chromatogram at each wavelength observed, it is found that the absorption of each peak is higher at 265nm, and the baseline of spectra is smooth. Therefore, the detection wavelength is finally decided as 265nm. 2.3.2 Chromatography conditions
In the experiment, several mobile phases are adopted in order to determine the optimal mobile phase. See Table 1.
Table 1 Mobile phase and Elution procedure 0.05% phosphate buffered saline (%)
I EE
IE EE ow sf es 2.3.3 Durability
Several sanguisorba tannins extracts from one batch are tested by using three chromatographic columns from different manufacturers under different brands respectively. Resolution and numbers of chromatographic peaks are used to evaluate the durability of instruments.
In the selected chromatographic conditions, the chromatogram and the resolution of each peak obtained from the annular column is superior to those from other two chromatographic columns. Therefore, the annular column is adopted.
In view of the foregoing, chromatography conditions are determined as follows:
Annular chromatographic column (4.6mm*250mm, Sum); DAD detector;
Gradient elution procedure with methanol-0.05% phosphate buffered saline: 0 min—80min, Methanol 5% —45%, 0.05% Phosphate buffered saline 95% — 55%;
80min—90min, Methanol 45% — 55%, 0.05% Phosphate buffered saline 45%—>95%; 91min—100min, Methanol 5%—5%, 0.05% Phosphate buffered saline 95% —>95%;
Detection wavelength: 265nm; Column temperature: 30°C; Flow rate: 1.0ml/min;
Run time: 100min. 2.3.4 Specialization
Sample solution is prepared in accordance with the above Item 2, and the detection is conducted as in accordance with the chromatographic method in the following Item “3”. Chromatographic peaks, its reserved time and peak areas within 90min are recorded. 10ul of water solution and 10ul of mixed control solution are accurately weighted out respectively, and then injected into a HPLC system. The chromatogram is recorded in 90min, and the chromatogram of each control substance is also recorded. Results show that no interference is observed under this condition. 2.3.5 Measurement of content 3. Measurement of total saponins and sanguisorbin I in the sanguisorba tannins extract
The measurement method is as follows. 1) Measurement of the content of total saponins
Preparation of control solution. 50mg of sanguisorbin I is added in a 10ml volumetric flask. Then about 9ml of anhydrous ethanol is added to dissolve the sanguisorbin I by ultrasonic. After being cooled, the solution is diluted to reach the graduation line with anhydrous ethanol, thus obtaining the control solution (0.5mg per
Iml).
Preparation of Standard curve. 0, 200ul, 300ul, 400ul, 500ul, 600ul, 800ul, and 1000ul of the control solution is sucked into eight of 10ml test tubes with cover respectively. Iml of 8% newly-prepared Vanilin-ethanol solution (obtained by diluting 8g of Vanilin with anhydrous ethanol to 100ml) and 10ml of 70% sulfuric acid (obtained by slowly adding 70ml of sulfuric acid into 30ml of water) are accurately added in each tube, mixed well and sealed. Each tube is placed in a water bath with a temperature of 60°C for 15 min, then cooled in ice water for 2min, and mixed well.
The absorbency at a wavelength of 530nm is determined according to the spectrophotometry (Appendix VIB) with the colorimetric solution with control substance as the blank test. Then, the standard curve can be obtained with the absorbency as Y-axis against the concentration as X-axis.
Preparation of sample solution. About 5g of sanguisorba tannins extract is ground, and weighed out accurately and put in a 250ml volumetric flask. About 200ml of anhydrous ethanol is added and the solution is extracted by ultrasonic for 30min, and then filtered. The filtrate is collected in a 250ml volumetric flask, and diluted to reach the graduation line with anhydrous ethanol.
Measurement
Accurately 1ml of sample solution is weighed out and transferred to a 10ml test tube with a cover. The absorbance is determined according to the method in the part of preparation of standard curve, and calculated in the regression equation. 2) Measurement of the content of sanguisorbin I
Chromatography conditions. Chromatographic column: Agilent-Zorbax (4.6mm* 250mm, Sum); mobile phase, acetonitrile: water (32:68); flow rate: 1.0ml/min; column temperature: 30°C; evaporative light-scattering detector.
Preparation of control solution. 25mg of sanguisorbin I is added in a 25ml volumetric flask. Then about 20ml of anhydrous ethanol is added to dissolve the sanguisorbin I by ultrasonic. After being cooled, the solution is diluted to reach the graduation line with anhydrous ethanol, thus obtaining the control solution (1mg per
Iml).
Preparation of standard curve. 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml of the above control solutions are sucked into five of 5ml volumetric flasks respectively. Each solution is diluted to reach the graduation line with anhydrous ethanol. Accurately 10ul of each solution is used for measurement under the above chromatography conditions. A standard curve is obtained with the natural logarithm of peak area as Y- axis and the natural logarithm of sample amount as X-axis.
Preparation of sample solution. About 5g of sanguisorba tannins extract is ground, and weighed out accurately and transferred in a 100ml volumetric flask.
About 90ml of anhydrous ethanol is added and the solution is extracted by ultrasonic for 30min. After being cooled, the solution is diluted to reach the graduation line with anhydrous ethanol, shaken well, and then filtered through a filtering head with micropores of 0.45 um, thus obtaining the sample solution.
Measurement
Accurately 10ul of sample solution is weighed out, measured under the above chromatography conditions, and calculated in the regression equation.
Example 1 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then flash extracted with 70% acetone for 2 times, each for 2min.
The solvent amount is 10 times of the powders in the first extraction, and § times in the second extraction. Then, the filtrates are merged and concentrated under reduced pressure. The concentrate is extracted and defatted by ethyl ether with a volume ratio of 1:1 until the ethyl ether layer is colorless, and then the mother liquor is further extracted by ethyl acetate with a volume ratio of 1:1 to enrich total phenols for 6 times.
The ethyl acetate solution is merged and concentrated at a low temperature 45°C under reduced pressure to a proper amount, and dried at 45°C under reduced pressure.
Thus the sanguisorba tannins extract can be obtained.
Results: the extract contains 62% (w/w) of tannins, 1.32% (w/w) of sanguiin, 2.61% (w/w) of catechin, 0.08% (w/w) of proanthocyanidin B2, 6.2% (w/w) of sanguisorba saponins, and 3.7% (w/w) of sanguisorbin I.
Example 2 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then reflux extracted with 70% acetone for 3 times, each for 2h.
The solvent amount is 10 times of the powders in the first extraction, 8 times in the second extraction, and 6 times in the third extraction. Then, the filtrates are merged and concentrated under reduced pressure. The concentrate is extracted and defatted by ethyl ether with a volume ratio of 1:1 until the ethyl ether layer is colorless, and then the mother liquor is further extracted by ethyl acetate with a volume ratio of 1:1 to enrich total phenols for 6 times. The ethyl acetate solution is merged and concentrated at a low temperature 45°C under reduced pressure to a proper amount, and dried at 45°C under reduced pressure. Thus the sanguisorba tannins extract can be obtained.
Results: the extract contains 65% (w/w) of tannins, 1.41% (w/w) of sanguiin, 2.65% (w/w) of catechin, 0.09% (w/w) of proanthocyanidin B2, 5.4% (w/w) of sanguisorba saponins, and 3.1% (w/w) of sanguisorbin I.
Example 3 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then reflux extracted with 70% ethanol for 3 times, each for 2h.
The solvent amount is 10 times of the powders in the first extraction, 8 times in the second extraction, and 6 times in the third extraction. Then, the filtrates are merged and concentrated under reduced pressure. The concentrate is extracted and defatted by ethyl ether with a volume ratio of 1:1 until the ethyl ether layer is colorless. The concentrate is separated by macroporous resin, wherein it is firstly eluted by water to colorless, then by 10% ethanol with an amount of twice of the column volume, finally by 60% ethanol with an amount of twice of the column volume. The 60% ethanol cluent is collected, and concentrated at 55°C under reduced pressure to a proper amount. After spray drying, the sanguisorba tannins extract can be obtained.
Results: the extract contains 73% (w/w) of tannins, 1.52% (w/w) of sanguiin, 2.88% (w/w) of catechin, 0.11% (w/w) of proanthocyanidin B2, 3.2% (w/w) of sanguisorba saponins, and 1.7% (w/w) of sanguisorbin I.
Example 4 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then reflux extracted with 70% ethanol for 3 times, each for 2h.
The solvent amount is 10 times of the powders in the first extraction, 8 times in the second extraction, and 6 times in the third extraction. Then, the filtrates are merged and concentrated under reduced pressure. The precipitate is removed, and the supernate is separated by macroporous resin, wherein it is firstly eluted by water to colorless, then by 10% ethanol with an amount of twice of the column volume, finally by 60% ethanol with an amount of twice of the column volume. The 60% ethanol eluent is collected, and concentrated through film to a proper amount. After spray drying, the sanguisorba tannins extract can be obtained.
Results: the extract contains 79% (w/w) of tannins, 1.72% (w/w) of sanguiin, 3.24% (w/w) of catechin, 0.13% (w/w) of proanthocyanidin B2, 2.4% (w/w) of sanguisorba saponins, and 1.3% (w/w) of sanguisorbin I.
Example S Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then decocted with water for 3 times, each for 2h. The water amount is 10 times of the powders in the first decoction, 8 times in the second decoction, and 6 times in the third decoction. Then, the filtrates are merged and concentrated under reduced pressure to a proper amount. The precipitation is removed.
The solution is separated by macroporous resin, wherein it is firstly eluted by water to colorless, then by 10% ethanol with an amount of twice of the column volume, finally by 60% ethanol with an amount of twice of the column volume. The 60% ethanol eluent is collected and concentrated at 55°C under reduced pressure to a proper amount. After spray drying, the sanguisorba tannins extract can be obtained.
Results: the extract contains 61% (w/w) of tannins, 1.22% (w/w) of sanguiin, 2.43% (w/w) of catechin, 0.07% (w/w) of proanthocyanidin B2, 6.9% (w/w) of sanguisorba saponins, and 4.3% (w/w) of sanguisorbin I.
Example 6 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name:Radix Sanguisorbae) is ground into coarse powders and then decocted with water for 3 times, each for 2h. The water amount is 10 times of the powders in the first decoction, 8 times in the second decoction, and 6 times in the third decoction. Then, the filtrates are merged and concentrated under reduced pressure to a proper amount. The precipitation is removed.
The solution is separated by macroporous resin, wherein it is firstly eluted by water to colorless, then by 10% ethanol with an amount of twice of the column volume, finally by 60% ethanol with an amount of twice of the column volume. The 60% ethanol eluent is collected and concentrated through film to a proper amount. After spray drying, the sanguisorba tannins extract can be obtained.
Results: the extract contains 67% (w/w) of tannins, 1.34% (w/w) of sanguiin, 2.59% (w/w) of catechin, 0.08% (w/w) of proanthocyanidin B2, 5.5% (w/w) of sanguisorba saponins, and 3.4% (w/w) of sanguisorbin I.
Example 7 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then flash extracted with 70% acetone for 2 times, each for 2min.
The solvent amount is 10 times of the powders in the first extraction, and § times in the second extraction. Then, the filtrates are merged and concentrated through film to a proper amount. The solution is separated by macroporous resin, wherein it is firstly eluted by water to colorless, then by 10% ethanol with an amount of twice of the column volume, finally by 60% ethanol with an amount of twice of the column volume. The 60% ethanol eluent is collected and concentrated through film to a proper amount. After spray drying, the sanguisorba tannins extract can be obtained.
Results: the extract contains 78% (w/w) of tannins, 1.69% (w/w) of sanguiin, 3.35% (w/w) of catechin, 0.13% (w/w) of proanthocyanidin B2, 3.1% (w/w) of sanguisorba saponins, and 1.4% (w/w) of sanguisorbin I.
Example 8 Preparation of sanguisorba tannins extract of the present invention
Coarse powders of Garden Burnet Root (scientific name: Radix Sanguisorbae) is warmly immersed in water in an amount of 12 times of the powders twice, each 3h.
After filtration, the filtrates are merged, concentrated to 0.5g crude per ml and is placed in a centrifuge. It is centrifuged for 10min at the speed of 4000 rpm, and the supernate is collected. The supernate is slowly fed to D-101 marcoporous resin with a diameter height ratio of 1:5 at 2BV/h. After a static adsorption for 30min, it is washed with 2BV water at 2BV/h, and then washed with 1BV 10% ethanol at 2BV/h, finally eluted with 2BV 60% ethanol at 1BV/h. The eluent is collected, concentrated and dried.
Results: the extract contains 55% (w/w) of tannins, 7.2% (w/w) of sanguisorba saponins, and 4.9% (w/w) of sanguisorbin I. The yield of tannins in the present invention is up to 13%.
For ten batches of sanguisorba tannins prepared according to Example 8, the contents of sanguiin, catechin, and proanthocyanidin B2 therein are determined.
Results are shown as follows.
Table 2 Content determination of ten batches of sanguisorba tannins extracts uesu | ve | as | 00noses | tes | 297 | 0 000
The average content of sanguiin, catechin, and proanthocyanidin B2 is 1.61% (w/w), 3.02% (w/w), and 0.12% (w/w) respectively.
Example 9 Preparation of sanguisorba tannins extract of the present invention
The Garden Burnet Root (scientific name: Radix Sanguisorbae) is ground into coarse powders and then decocted with water for 2 times, each for 1.5h. The water amount is 10 times of the powders in the first decoction, and 8 times in the second decoction. Then, the filtrates are merged and concentrated under reduced pressure to a proper amount. The precipitation is removed. The solution is separated by macroporous resin, wherein it is firstly eluted by water to colorless, then by 10% ethanol with an amount of twice of the column volume, finally by 60% ethanol with an amount of 3 times of the column volume. The 60% ethanol eluent is collected and concentrated under reduced pressure to a proper amount. After the concentrated solution is spray dried, it is dissolved in water, and then the obtained solution is stood for 1h, and the precipitation is filtered. The filtrate is placed in an evaporating dish, into which gelatin solution is sprayed slowly. After standing for 1h, the precipitation is collected, and taken out after freeze dried for 12h. The precipitation is then ground into fine powders, and resolved with 90% acetone for 2h. The obtained solution is fully distilled at 45°C under reduced pressure to recover acetone, and the concentrate is poured out and freeze dried for 12h. Thus highly purified sanguisorba tannins with the tannins content of 98.5% can be obtained.
I. The content of sanguiin, catechin, and proanthocyanidin B2 is 2.29% (w/w), 4.85% (w/w), and 0.38% (w/w), respectively. 2. Determination of the content of Tannins
The content of tannins is determined according to Appendix XB of Chinese
Pharmacopoeia (2010 Edition, Volume 1):
The experiment should be performed away from light.
Preparation of control solution. 48.30 mg of gallic acid as control substance is weighed out accurately and added into a 100ml brown volumetric flask. Water is added to dissolve the gallic acid and dilute it until the solution reaches the graduation line. 5ml of the solution is weighed out accurately, and added into a 50ml brown volumetric flask. Water is added to dilute the solution until it reaches the graduation line. The solution is then shaken well, thus obtaining the control solution with 0.0483mg gallic acid per 1ml solution.
Preparation of standard curve. 0.5ml, 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml of control solutions are weighed out accurately and added into six 25ml brown volumetric flasks respectively. 1ml of phosphomolybdium tungstic acid solution is added to each of the above flasks, and then 11.50ml, 11ml, 10ml, 9ml, 8ml and 7ml of water are added therein respectively. Each solution is then diluted with 29% sodium carbonate solution to reach the graduation line and shaken well. After the obtained solution is stood for 30 min, the absorbency at a wavelength of 760nm is determined according to UV-VIS spectrophotometry (Appendix VA) with the corresponding reagent as the blank test. Then, the standard curve can be obtained with the absorbancy as Y-axis against the concentration as X-axis. :
Y =0.118 X + 0.046 (R= 0.999) ee | se
Preparation of sample solution. 0.101g, 0.105g and 0.997g of extract powders are weighed out accurately, and then added into three 250ml brown volumetric flasks respectively. 150ml of water are added in the three flasks respectively. Each solution is stood for night and then treated by ultrasonic for 10 min. After being cooled, it is diluted with water to reach the graduation line. The solution is shaken well and stood so as to enable solids to precipitate from the solution. The solution is filtered, and 50ml of preliminary filtrate is abandoned, whereas 20ml of residual filtrate is weighed out accurately and then transferred into a 100ml brown volumetric flask. Then, the obtained solution is diluted with water to the graduation line and shaken well, thus obtaining the sample solution.
Measurement
Total phenols. 2ml of sample solution is weighed out accurately and added into a 25ml brown volumetric flask. According to the method provided in the part of “preparation of standard curve”, after “Iml of phosphomolybdium tungstic acid solution is added”, 10ml of water is added. The absorbance is determined in known manner, and the weight (mg) of gallic acid in the sample solution can be read out from the standard curve. Thus the content of total phenols can be obtained by calculation. Non-adsorbed polyphenols. 25ml of sample solution is weighed out accurately and then transferred to a 100ml conical flask filled with 0.6g of casein. The flask is sealed with a cover and placed in a water bath with a temperature of 30°C for th. The flask is constantly shaken, and then removed from the water bath and cooled.
The solution is shaken well and filtered, and the preliminary filtration is abandoned. 2ml of residual filtration is weighed out accurately, and then transferred into a 25ml brown volumetric flask. According to the method provided in the part of “preparation of standard curve”, after “1ml of phosphomolybdium tungstic acid solution is added”, 10ml of water is added. The absorbance is determined in known manner, and the weight (mg) of gallic acid in the sample solution can be read out from the standard curve. Thus the content of non-adsorbed phenols can be obtained by calculation.
The content of tannins can be calculated as follows: the amount of tannins = the amount of total phenols — the amount of non-adsorbed polyphenols.
Weight (g) phenols (%) polyphenols (%) Tannins (%) (%) (1 Jour eso Jos fess 98.5 3. Determination of total saponins and sanguisorbin I in the sanguisorba tannins extract
Three batches of tannins extract are determined, with no peak of sanguisorbin I can be observed with HPLC analysis. The absorbance of total saponins determined by
UV spectrophotometry is 0.001. It can be concluded that the content of total saponins is less than 0.001% and the content of sanguisorbin I is less than 0.0001%. Therefore, when the content of tannins are more than or equal to 98%, the content of total saponins and sanguisorbin I is substantially zero.
In combination with the results of the contents of sanguiin, catechin, and proanthocyanidin B2 in Examples 1-9, it can be found that the contents of sanguiin, catechin, and proanthocyanidin B2 in the sanguisorba tannins extract of the present invention are relatively stable. Specifically, said extract contains 0.05%-3.0% (w/w) of sanguiin, 1.0%-5.0% (w/w) of catechin, and 0.05%-1.5% (w/w) of proanthocyanidin B2. Preferably, said extract contains 1.0%-2.0% (w/w) of sanguiin, 2.0%-4.0% (w/w) of catechin, and 0.05%-4% (w/w) of proanthocyanidin B2.
Example 10 Optimized process of purifying sanguisorba tannins with macroporous resin 1 Type of resin 1.1 Experimental method 15g of dried macroporous resin is weighted out and transferred in a 100ml conical flask sealed with a cover. 50ml of 2% hydrochloric acid is added for immersion of 3h, and then the solution is washed with water to a neutral pH value.
Subsequently, 50 ml of 2% NaOH solution is added for immersion of 3h, and the resin is activated through adding 60ml of 95% alcohol. 50ml of the sanguisorba tannins extract solution (0.33g/ml) is weighted out and placed in a conical flask containing activated macroporous resin sealed with a cover, enabling macroporous resin fully soaked in the solution for 24h. The volume of the residual liquid in the conical flask is determined, thus obtaining the adsorption amount of macroporous resin. The macroporous resin is removed from the conical flask and then immersed in 95% ethanol and then treated by ultrasonic for 1h. The content of tannins in the eluent is determined, thus obtaining the clution efficiency based on the contents of tannins before and after adsorption respectively.
Maximum adsorbance = (the content of tannins before adsorption - the content of tannins after adsorption)/mass of macroporous resin.
Elution efficiency = the content of tannins in the eluent/(the content of tannins before adsorption - the content of tannins after adsorption).
Based on the maximum adsorbance and the elution efficiency of DA-201, D-101,
LSA-20, HP-10 or AB-8 macroporous resins, a suitable type of resin is selected. 1.2 Results
Table 3 shows the data from the experiment.
Table 3 Selection of resin maximum absorbance (g/g) elution efficiency (%)
DA-201 0.106 72.41
D-101 0.120 76.52
LSA-20 0.097 62.76
HP-10 0.102 68.45 10d i:
From the above experiment it can be confirmed that macroporous resin is of good adsorption and elution capability for sanguisorba tannins. Therefore, macroporous resin can be selected for purifying sanguisorba tannins, wherein in the present invention macroporous resin is preferably D-101. 2 The leakage curve of D-101 macroporous resin 20g of pretreated D-101 macroporous resin is packaged in column, which has a column volume of 30.4cm’ and a diameter height ratio of 1:4. 60ml of sanguisorba tannins extract solutions (0.33g crude per ml) as sample is fed in a dynamic manner at a controlled flow speed of 0.77ml/min constantly. The effluent from the column bottom is collected for 11 bottles, each of 5ml. For each effluent the content of tannins therein is determined respectively. Thus the leakage curve of macroporous resin can be obtained, and a leakage curve with the content of tannins as Y-axis and the volume as X-axis can be drawn.
Iml of the effluent is transferred accurately from each bottle, and diluted to 100ml with water. 2ml of the diluted solution is transferred accurately into a 25ml brown volumetric flask. 1ml of phosphomolybdium tungstic acid solution is added to the flask, and then 10ml of water is added therein. The solution is then diluted with 29% sodium carbonate solution to reach the graduation line. After the solution is stood for 30 min, the absorbance is determined. Then, the weight (mg) of gallic acid in the sample solution can be read out from the standard curve.
Table 4 Data of the leakage curve of D-101 macroporous resin
In summary, the solution starts to leak out at 30ml. The optimized sample volume is 30ml, with a concentration of 0.33g crude per ml and an amount of 20g macroporous resin. Therefore, the optimized ratio of the amount of raw material to that of macroporous resin is 1:2. 3 The elution curve 60ml of sanguisorba tannins extract solution (0.33g crude per ml) is used. 20g of
D-101 macroporous resin is packaged in column, which has a column volume of 30.4cm’ and a diameter height ratio of 1:4. The flow rate for feeding sample is kept constant. After adsorption of 1h till saturation, the solution is eluted with a column volume of water, 10% cthanol, 30% cthanol, 50% cthanol, 70% cthanol and 90% ethanol respectively at a constant flow speed. The eluent is collected and the content of tannins therein is determined. The influences of different eluent concentrations on macroporous resin are compared with each other. 0.5ml of the eluent is diluted to 100ml, from which accurately 2ml of sample solution is weighted out and placed in a 25ml brown volumetric flask. Iml of phosphomolybdium tungstic acid solution is added to the flask, and then 10ml of water is added therein. The solution is then diluted with 29% sodium carbonate solution to reach the graduation line. After the solution is stood for 30 min, the absorbency is determined. Then, the weight (mg) of gallic acid in the sample solution can be read out from the standard curve, thus obtaining the elution curve by calculation. The experimental data are shown in Table 5.
Table 5 Influence of different eluents on the elution curve
With the elution curve and the actual production cost taken into consideration, 60% ethanol is selected for eluting tannins. 4 Optimizing process parameters by uniform design
The content of tannins, the conversion rate and the value of overall desirability (OD value) are used to evaluate the influences of five levels of each of the diameter height ratio, the concentration of sample solution, the flow rate and the amount of 60% ethanol on the purification effect of tannins by a Us(5") uniform design table.
The factors and levels adopted in the uniform design are shown in Table 6, and the experimental data are shown in Table 7.
Table 6 Factors and levels of the uniform design table
A B C D
WX diameter height ratio 60% ethanol flow rate concentration of sample solution
0s | wf 2s | asf 0s 4 | ow fous fs) 0s
Table 7 Experimental data of the uniform design 1 [ssa fesse Jes
By analyzing the results with spssl7.0 software, the main output result displays a selected x3, R2=0.85, and variance analysis reveals F=16.192, P=0.026. Stepwise regression is statistically suitable.
Anova’ sum of mean
Resa | on | a |e |]
Cw aw a. predicting variable: (constant), x3 b. dependent variable: y
Equation coefficients, partial regression coefficient t of x3=-4.112, unilateral
P=0.026, reserved. That is, the regression equation is y=1.092-0.172x3. Since x3 in the regression equation is minus and there is no x, X; and x4, the value of x3 should be the minimum in the test scope. According to the actual conditions, x;=1:5, x,=2 and x4=0.5. The approximate evaluation at the optimal point is x3=1. Therefore, the optimized parameters are as follows: diameter height ratio is 1:5, concentration of sample solution is 0.5, flow rate is 1BV/h, and the amount of 60% ethanol is 2 times of the column volume.
Coefficients standard 95.0%
Non-standard |coefficien confidence |Multicollinearity standard | trial Low | Upon 1 |(con| 1.092 | .089 12.308 | .001 810 | 1.374 stan a. dependent variable: y
Verification test of process for purifying sanguisorba tannins by macroporous resin
According to the above optimized process, the OD value is predicted as 0.92, which is verified as follows.
Table 8 verification for the process (HPLC)
The results show that the purification process results are relatively stable. 6 Summary
According to the above experimental results, the purification conditions for sanguisorba are as follows. A sanguisorba extract solution, after being concentrated to 0.5g crude per ml, is placed in a centrifuge. It is centrifuged for 10min at the speed of 4000 rpm, and the supernate is collected. The supernate is slowly fed to D-101 resin column with a diameter height ratio of 1:5 at 2BV/h. After a static adsorption for 30min, it is washed with 2BV water at 2BV/h, and then washed with 1BV 10% ethanol at 2BV/h, finally eluted with 2BV 60% ecthanol at 1BV/h. The eluent is collected, concentrated and dried.
In practice, other macroporous resins can be selected for purifying sanguisorba tannins. The yield of sanguisorba tannins extract reported in prior arts is very low,
averagely less than 10%. However, the extraction efficiency in the present invention is higher than 13%.
The beneficial effect of the present invention is proved by the following pharmacodynamics tests.
Test 1 Protective effect of the sanguisorba tannins in the present invention on bone marrow 1. Sanguisorba tannins extract
Sanguisorba tannins extract with high purify prepared according to Example 9 is used, wherein the extract comprises 98.5% of tannins. 2. The pharmaceutical effect of Sanguisorba tannins against bone marrow inhibition caused by chemical substances 2.1 Experimental materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; High purity sanguisorba tannins (containing more than 98.5% of tannins); Cyclophosphamide for
Injection; Recombinant human granulocyte-colony stimulating factor (rhG-CSF, 751g); and Normal saline. 2.2 Experimental method 2.2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 60 mice are randomly divided into 6 groups by gender (see Table 9 for details), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for administration of an equivalent volume of normal saline to the blank group, other groups are injected intraperitoneally (ip) with Cyclophosphamide at 100mg/kg*d for 3 days based on the mouse body weight of the day. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day.
Table 9 Grouping of animals and dosage of drug administration
Low-dose group moderate-dose group high-dose group 2.2.2 Evaluation index and data treating
Blood is collected from orbits of mice at 7th day after modeling, and detected for parameters of peripheral blood routine by the Automatic Blood Cell Counter, including white blood cell (WBC) count, red blood cell (RBC), Hemoglobin (HGB), and platelet (PLT). Meanwhile, the spleens of mice are taken out and weighted, and the spleen coefficient is calculated. After executing the above treated mice, left-side intact femurs of mice are taken out and the soft tissue thereof are removed. The whole bone marrow is flushed into a test tube with 10ml of 0.005mol/L CaCl,. The tube is stood in a fridge at 4°C for 30min, and centrifuged at 2500r/min for 15min.
Supernate is removed, and the precipitate is sufficiently mixed with Sml of 0.2mol/L
HCIO,. After being heated at 90°C for 15min, the tube is cooled and then centrifuged at 3500r/min for 10min. Supernate is used to determine the OD value at a wavelength of 260nm by ELIASA.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 2.2.3 Result analysis
Table 10 shows the influence of sanguisorba tannins on the decrease of white blood cells, red blood cells and platelet of peripheral blood of mice caused by cyclophosphamide and spleen coefficient. Intraperitoneal injection of cyclophosphamide into the abdomens of mice will enable significant decreases of white blood cells, red blood cells and platelet in peripheral blood of mice, and also significant decreases of spleen coefficient and DNA contents in bone marrow. Thus a statistical difference presents compared with Blank group. Compared with Model group, it can be found that sanguisorba tannins high-dose group, sanguisorba tannins moderate-dose group and sanguisorba tannins low-dose group and rhG-CSF can significantly increase the counts of white blood cells (P<0.05), and improve spleen coefficient. Sanguisorba tannins high-dose group can significantly increase the counts of red blood cells and platelet in peripheral blood, while Sanguisorba tannins and rhG-
CSF do not affect Hemoglobin contents obviously. Sanguisorba tannins high-dose group can significantly improve DNA contents in bone marrow (P<0.05), while rhG-
CSF has a harmful effect on DNA contents in bone marrow.
Table 10 Pharmaceutical study on sanguisorba tannins against bone marrow inhibition caused by chemical substances (meantS.D., n=10)
Groups Dosage WBC RBC HGB PLT spleen DNA (mg/kg) (10°/L) (10'¥L) (g/L) 10°) coefficient | contents in (mg/10g) | bone marrow (ng) igen | sou [amon [www | swenn | pian oss otigow | |sawon [soon fuses | seni | som | ossse
Sanguisorba 2.5 3.87+0.39 4.11+0.55 135.8944.03 337.87+46.13 | 26.16+3.01 87.22+£3.26 tannins Low- dose group
Sanguisorba 5 4.55+0.47 4.27+0.75 133.834+12.63 368.33+54.72 | 29.86+4.23 94.28+7.98 tannins moderate-dose group
Sanguisorba 10 4.92+0.74% 4.650.770 135.80+14.79 386.74+50.54 | 32.44+4.20% | 106.32+8.93% tannins high- dose group
A:compared with Model group P<<0.05
It can be known from the above experiments that rhG-CSF can strongly improve white blood cells, enabling the count of white cells obviously greater than that in normal group (P<<0.05). However, thG-CSF cannot protect bone marrow, and even accelerate cell division in bone marrow through stimulation, thus further aggravating the load of hemopoietic stem cells. This is one reason to cause some side effects such as bone pain. As one of main cells used for adjusting bone marrow granulopoiesis,
RhG-CSF has a significantly beneficial treatment effect for leucopenia, erythropenia and thrombocytopenia caused by radiotherapy and/or chemotherapy. The mechanism thereof is as follows. RhG-CSF selectively influences on CFU-C, and directly accelerates cell proliferation and differentiation, and improves the function of granulopoietic cell terminal differentiation, thus rapidly increasing white blood cells.
The sanguisorba tannins of the present invention has a significantly protection (P<0.05) against the bone marrow inhibition of mice caused by cyclophosphamide, including obvious decrease of white blood cells, red blood cells, hemoglobin and platelet in peripheral blood and the decrease of DNA contents in bone marrow. It also exhibits a dose-dependent relationship: High>Moderate>Low. The sanguisorba tannins of the present invention comprises greater than 98.5% tannins and have a significantly beneficial treatment effect on bone marrow inhibition, leucopenia, erythropenia and thrombocytopenia caused by chemical substances. 3 The pharmaceutical effect of sanguisorba tannins against bone marrow inhibition caused by radiation 3.1 Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; Sanguisorba tannins (containing more than 98.5% of tannins); An external ray machine of Co-60 rays;
Recombinant human granulocyte-colony stimulating factor (rhG-CSF, 75ng); and
Normal saline. 3.2 Experimental method 3.2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 60 mice are randomly divided into 6 groups by gender (see §2), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for normal group, other groups all are placed in an isolated cycloid plastic box, defining distance based on the box cover as center. A total body irradiation 7.5Gy with Co-60 rays at dose rate of 82.6cGy/min is conducted with the irradiation distance of 80 cm. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-
CSF from 7th to 9th day. 3.2.2 Evaluation index and data processing
The count of White blood cells WBC is used as the observation index in the
Experiment.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 3.3 Result analysis
Table 11 shows the influence of sanguisorba tannins against the bone marrow inhibition caused by Co rays.
Table 10 Influence on sanguisorba tannins against bone marrow inhibition caused by Co rays (meantS.D., n=10)
Group Dosage WBC RBC HGB PLT Spleen DNA contents (mg/kg) (10°/L) (10/1) (g/L) (10°/L) coefficient in bone (mg/10g) marrow (jg) skew | emo asson | wisn | suns | sass | monen osc | [pon [sow | mins [woes | owas | nse
Sanguisorba 2.5 4.124+0.23 4.2340.54 137.904+10.12 397.12+60.36 24.26+4.03 91.3445.79 tannins Low- dose group
Sanguisorba 5 5.21+£0.43 4.45+0.54 137.234£7.89 421.36451.22 27.4543.54 102.54+6.98 tannins
Moderate-
wep || |} 0
Sanguisorba 10 6.010.424 4.77+0.54 139.024+12.43 413.57432.68 29.4342 46" 124.34+7.86*
SF dose group
A: P<<0.05, compared with Model group;
Sanguisorba tannins can also increase the numbers of red blood cells and plates (P<C0.05).
It can be seen from the above experiment that thG-CSF can strongly improve white blood cells, enabling the amount of white cells obviously greater than that in normal group (P<<0.05). However as mentioned in §2, DNA content in bone marrow of thG-CSF group is decreased.
The sanguisorba tannins of the present invention has a significantly protection (P<0.05) against the decrease of DNA contents in bone marrow of mice and the decrease of white blood cells caused by chemical substances. It also exhibits a dose- dependent relationship: High>Moderate>Low. The sanguisorba tannins produced by the present invention comprise greater than 98.5% tannins and have a significantly beneficial treatment effect on bone marrow inhibition, leucopenia, erythropenia and thrombocytopenia caused by chemical substances.
The Sanguisorba tannins of the present invention has a significantly protection (P<0.05) against the decrease of DNA contents in bone marrow of mice, and the decrease of white blood cells caused by Chemical substances, exhibiting a dose- dependent relationship: High>Moderate>Low. The sanguisorba tannins of the present invention comprises greater than 98.5% tannins. Test proves that the Sanguisorba tannins has a significantly beneficial treatment effect on bone marrow inhibition, leucopenia, erythropenia and thrombocytopenia caused by radiation.
Test 2 Pharmacological effect of sanguisorba tannins in the present invention and the components thereof
It is reported that Sanguisorba tannins contain sanguiin, catechin, proanthocyanidin B2, gallocatechin, epicatechin gallate, epicatechin and gallocatechin gallate (LIU Haiying, Component analysis and Function research on Sanguisorba polyphenols, Shaanxi Normal University, 2009). Therefore, the following experiment is performed in order to reveal the main active substances in the sanguisorba tannins of the present invention, and the activity thereof is compared with single compound.
1 Pharmaceutical effect of sanguisorba tannins and its components on bone marrow inhibition caused by chemical substances 1.1 Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group), ELASA; Cyclophosphamide for Injection; Recombinant human granulocyte-colony stimulating factor (rhG-CSF, 751g); Normal saline; High purity sanguisorba tannins (containing more than 98.5% of tannins, prepared according to Example 9); sanguiin (HPLC>99%); catechin (HPLC>99%); proanthocyanidin B2 (HPLC>99%); gallocatechin (HPLC>99%); epicatechin gallate (HPLC>99%); epicatechin (HPLC>99%); and gallocatechin gallate (HPLC>99%). All the above single compounds are purchased from Chengdu
Biopurify Phytochemicals Ltd. 1.2 Experimental method 1.2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 110 mice are randomly divided into 11 groups by gender (see Table 12 for details), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for administration of an equivalent volume of normal saline to the blank group, other groups are injected intraperitoneally (ip) with cyclophosphamide at 100mg/kg*d for 3 days based on the mouse body weight of the day. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day.
Table 12 Grouping of animals and dosage of drug administration
1.2.2 Evaluation index and data processing
The count of White blood cells WBC is used as the observation index in the
Experiment.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 1.2.3 Result analysis
Table 13 The Pharmacological effect of Sanguisorba tannins and its components on bone marrow inhibition caused by chemical substances (meantS.D., n=10)
Group Dose WBC RBC HGB PLT Spleen DNA contents (mg/kg) (10°/L) (10/1) (g/L) (10°) Coefficient in bone (mg/10g) marrow (ug) kn | eos amon sions sso | ngs | ors vost | oven | smoss | pene | mrss | wes | ose tannins group *
Gallocatechin 10 3.66019 | 3.914019 | 128.1940.09 | 315.1945831 | 25.0943.01 87.08+4.98 group
Epicatechin 10 3.714034 | 4112028 | 128.0148.02 | 321.33451.09 | 26.0945.02 90.03+3.98 gallate group
Proanthocyanidin | 10 417:028% | 4512025 | 129.9859.02 | 331.3246.78 | 28.99.4220 99.61+4.02%
B2 group
Epicatechin group
Gallocatechin 3.60+0.30 4.02+0.42 128.98+8.09 320.09£51.02 24.49+4.03 82.09+4.12 gallate group
A: P<0.05, compared with Model group;
Y¢: P<0.05, comparing sanguisorba tannins group with catechin group;
Sanguisorba tannins increase red blood cells and plates (P<0.05).
Experimental results show that the components, such as sanguiin, catechin, gallocatechin and epicatechin gallate etc., contained in the sanguisorba tannins can treat the bone marrow inhibition of mice caused by cyclophosphamide; especially, sanguiin, catechin and proanthocyanidin B2 have a significant effect (P<0.05), wherein among them sanguiin is strongest, catechin is followed, and proanthocyanidin
B2 is least. Moreover, given the same dosage, the effect of sanguisorba tannins is stronger than the component of sanguiin or catechin, revealing a synergistic effect exists among these components. 2 Pharmaceutical effect of sanguisorba tannins and its components on bone marrow inhibition caused by radioactivity 2.1 Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; An external ray machine of Co-60 rays; Recombinant human granulocyte-colony stimulating factor (rhG-CSF, 75pg); Normal saline; High purity sanguisorba tannins (containing more than 98.5% of tannins, prepared according to Example 9); sanguiin (HPLC>99%); catechin (HPLC>99%); proanthocyanidin B2 (HPLC>99%); gallocatechin (HPLC>99%); epicatechin gallate (HPLC>99%); epicatechin (HPLC>99%); and gallocatechin gallate (HPLC>99%). 2.2 Experimental method 2.2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 110 mice are randomly divided into 11 groups by gender (see §1), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for normal group, other groups all are placed in an isolated cycloid plastic box, defining distance based on the box cover as center. A total body irradiation 7.5Gy with
Co-60 rays at dose rate of 82.6cGy/min is conducted with the irradiation distance of 80 cm. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day. 2.2.2 Evaluation index and data processing
The same as Test 1. 2.3 Result analysis
Table 14 The pharmaceutical effect of Sanguisorba tannins and its components on bone marrow inhibition caused by radiation (meantS.D., n=10)
Group Dose WBC RBC HGB PLT Spleen DNA contents (mg/kg) 10°) (10/1) (g/L) 10°) Coefficient | in bone (mg/10g) marrow (ug) go || 902 [asso wns |smiesss | sian | ssooo otigow | | soon [secon | mine |main| wos | nmar
Sanguisorba 10 6.11+0.38 | 4.751049 139.284+11.34 411.37£31.76 30.1243.01% | 130. 2248.29% tannins group ak *
A
A
Gallocatechin 10 3.61+0.19 | 4.02+0.33 128.32410.09 331.98+41.32 23.0943.98 91.97+4.09 group
Epicatechin Gallate | 10 3.47+0.18 | 3.9840.51 129.3148.12 348.29+49.25 22.8945.02 92.1945.09 group
EFS I EE A
Fl 3.594026 | 3.854041 128.25411.01 301.78+49.78 24.9945.01 91.09+£7.01 gallate group
A: P<0.05, compared with Model group;
Y¢: P<0.05, comparing sanguisorba tannins group with catechin group;
Sanguisorba tannins can also increase red blood cells and plates etc. (P<0.05).
Experimental results show that the components, such as sanguiin, catechin, gallocatechin and epicatechin gallate etc., contained in the sanguisorba tannins can treat the bone marrow inhibition of mice caused by radiation; especially, sanguiin, catechin and proanthocyanidin B2 have a significant effect (P<0.05), wherein among them sanguiin is strongest, proanthocyanidin B2 is followed, and catechin is least.
Moreover, given the same dosage, the effect of sanguisorba tannins is stronger than the component of sanguiin, catechin or proanthocyanidin B2, revealing a synergistic effect exists among these components.
In summary, the main active ingredients of sanguisorba tannins against bone marrow inhibition and the decrease of white blood cells, red blood cells and the platelets caused by chemical damages and radiation damages are sanguiin, proanthocyanidin B2 and catechin, wherein sanguiin has a stronger function for two model therapies, while proanthocyanidin B2 and catechin have their own different focus. That is, catechin has a better protection for chemical damages, while proanthocyanidin B2 directs to the protection for physical trauma. The foregoing also reveals that a synergistic effect exists among the components of sanguisorba tannins.
The above experiments sufficiently prove that sanguisorba tannins are able to function against the bone marrow inhibition caused by chemical damages and radiation damages, and the decrease of white blood cells, red blood cells and platelets.
Therefore, it can be predicted that due to the protection against bone marrow inhibition, sanguisorba tannins is very optimistic in clinical application in the combination treatment of anti-tumor.
Since in prior arts it is reported that sanguisorba saponins are active substances for increasing white blood cells. Inventors cautiously conducted a series of experiments to further study material basic of sanguisorba for increasing white blood cells.
Test 3 Material basic for sanguisorba tannins’ function of increasing white blood cells in the present invention 1 Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; High purity sanguisorba tannins (containing more than 98.5% of tannins, prepared according to
Example 9); Cyclophosphamide for Injection; Recombinant human granulocyte- colony stimulating factor (rhG-CSF, 75g); Normal saline. 2. Experimental method 2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 70 mice are randomly divided into 7 groups by gender (see Table 15 for details), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for administration of an equivalent volume of normal saline to the blank group, other groups are injected intraperitoneally (ip) with cyclophosphamide at 100mg/kg*d for 3 days based on the mouse body weight of the day. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day.
Table 15 Grouping of animals and dosage of drug administration tannins extract tannins extract
High-dose of sanguisorba | sanguisorba tannins extract (10mg/kg-d), | 10
ET removed
Low-dose of sanguisorba | sanguisorba tannins extract (2.5mg/kg-d), | 10
Erm removed 2.3 Evaluation index and data processing
The count of White blood cells WBC is used as the observation index in the
Experiment.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 3. Result analysis
By analyzing the experimental results of white blood cells WBC in Table 16, it can be seen that: (1) There are significant differences between blank group and model group (P<0.05), which indicates the modeling for animal models of mice leukopenia caused by cyclophosphamide is successful; (2) There are significant differences among high-dose group of sanguisorba tannins, low-dose group of sanguisorba tannins, positive group and model group (P<0.05), which indicates sanguisorba tannins have a beneficial treatment effect on mice leukopenia caused by cyclophosphamide; there are no significant differences between other drug administration groups and model groups (P>0.05), which indicates other drug administration groups have no treatment effect on leukopenia caused by cyclophosphamide; (3) The efficacy strength of sanguisorba tannins exhibits an obvious dose-dependent relationship: high-dose>low-dose (P<0.05).
Table 16 Experimental results about white blood cells WBC (meantS.D., n=10)
removed removed
A: P<0.05, compared with model group
Yi: P<0.05, compared with groups with tannins removed
Test 4 Material basic for the function of improving white cells of Sanguisorba tannins extract in the present invention. 1 Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; Sanguisorba tannins (prepared according to Example 8, containing 55% of tannins, 1.61% of sanguiin, 3.02% of catechin, and 0.12% of proanthocyanidin B2, 7.2% of sanguisorba saponins, and 4.9% of sanguisorbin, all calculated by weight); Cyclophosphamide for Injection;
Recombinant human granulocyte-colony stimulating factor (rhG-CSF, 75g); Normal saline. 2. Experimental method 2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 70 mice are randomly divided into 7 groups by gender (see Table 17 for details), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for administration of an equivalent volume of normal saline to the blank group, other groups are injected intraperitoneally (ip) with cyclophosphamide at 100mg/kg*d for 3 days based on the mouse body weight of the day. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day.
Table 17 Grouping of animals and dosage of drug administration tannins extract tannins extract
High-dose of sanguisorba | sanguisorba tannins extract (10mg/kg-d), | 10 tannins extract, tannins | tannins removed by Gelatin removed
Low-dose of sanguisorba | sanguisorba tannins extract (2.5mg/kg-d), | 10 tannins extract, tannins | tannins removed by Gelatin removed 2.3 Evaluation index and data processing
The count of White blood cells WBC is used as the observation index in the
Experiment.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 3. Result analysis
By analyzing the experimental results of white blood cells WBC in Table 18, it can be seen that: (1) There are significant differences between blank group and model group (P<0.05), which indicates the modeling for animal models of mice leukopenia caused by cyclophosphamide is successful; (2) There are significant differences among high-dose group of sanguisorba tannins, low-dose group of sanguisorba tannins, positive group and model group (P<0.05), which indicates sanguisorba tannins have a beneficial treatment effect on mice leukopenia caused by cyclophosphamide; there are no significant differences between other drug administration groups and model groups (P>0.05), which indicates other drug administration groups have no treatment effect on leukopenia caused by cyclophosphamide; (3) The efficacy strength of sanguisorba tannins exhibits an obvious dose-dependent relationship: high-dose > low-dose (P<0.05).
Table 16 Experimental results about white blood cells WBC (meantS.D., n=10) removed removed
A: P<0.05, compared with model group
Ye: P<0.05, compared with group with tannins removed 4. Conclusion
Tests 3 and 4 indicate that sanguisorba tannins extract of the present invention has a significant treatment effect on mice leukopenia caused by cyclophosphamide (P<0.05); moreover, after removing tannins by Gelatin, sanguisorba tannins extract has no treatment effect, which further proves that sanguisorba tannins are active ingredients for treating leucopenia.
Test S Sanguisorba saponins’ function of increasing white blood cells and protecting bone marrow 1 Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; Sanguisorba tannins extract (98.18%); Cyclophosphamide for Injection; Recombinant human granulocyte- colony stimulating factor (rhG-CSF, 75ug); and Normal saline.
Preparation of sanguisorba saponins. The Garden Burnet Root (scientific name:
Radix Sanguisorbae) is ground into coarse powders and then reflux extracted with 70% ethanol for 3 times, each for 1.5h. The solution is concentrated to a proper amount (no alcohol flavor) at 70°C under reduced pressure. The concentrate is transferred to a separating funnel, defatted with water-saturated ether twice. The mother liquor is treated at 70°C under reduced pressure to recover the residual ether, then dissolved in water, and extracted twice with water-saturated n-butanol. The extract is then condensed at 80°C under reduced pressure, and solids therein are dissolved through adding ethanol with a certain concentration. The solution is transferred to a beaker, with an appropriate amount of water added to adjust the pH value within the range of 10-14. After standing and being centrifuged, the precipitation is removed. After vacuum drying for 2 hours at 70°C, it is transferred to a triangular flask with a cover, and extracted by ultrasonic through adding anhydrous ethanol. After filtration, the filtrate is condensed at 70°C under reduced pressure to recover ethanol, till to just form precipitation. Then, it is transferred to an evaporation dish, where ethanol is volatilized in a water bath at 80°C. After vacuum drying for 12 hours at 70°C, the residual is taken out and ground. Sanguisorba saponins: 98.18%. 2 Experimental method 2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 60 mice are randomly divided into 6 groups by gender (see Table 9 for details), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for administration of an equivalent volume of normal saline to the blank group, other groups are injected intraperitoneally (ip) with Cyclophosphamide at 100mg/kg*d for 3 days based on the mouse body weight of the day. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day.
Table 19 Grouping of animals and dosage of drug administration tannins
Sanguisorba tannins tannins 2.2 Evaluation index and data processing
Blood is collected from orbits of mice at 7th day after modeling, and detected for parameters of peripheral blood routine by the Automatic Blood Cell Counter, including white blood cell (WBC) count, red blood cell (RBC), Hemoglobin (HGB), and platelet (PLT). Meanwhile, the spleens of mice are taken out and weighted, and the spleen coefficient is calculated. After executing the above treated mice, left-side intact femurs of mice are taken out and the soft tissue thereof are removed. The whole bone marrow is flushed into a test tube with 10ml of 0.005mol/L CaCl. The tube is stood in a fridge at 4°C for 30min, and centrifuged at 2500r/min for 15min. Supernate is removed, and the precipitate is sufficiently mixed with 5ml of 0.2mol/L. HCIOa.
After being heated at 90°C for 15min, the tube is cooled and then centrifuged at 3500r/min for 10min. Supernate is used to determine the OD value at a wavelength of 260nm by ELIASA.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 2.2.3 Result analysis
Table 20 shows the influence of sanguisorba saponins extract on the decrease of white blood cells, red blood cells and platelet in peripheral blood of mice caused by cyclophosphamide and the spleen coefficient. Compared with the model group, high- dose group, moderate-dose group and low-dose group of Sanguisorba saponins extract have no significant influence on increasing white blood cells (P>0.05), and also no treatment effect on bone marrow inhibition caused by cyclophosphamide (P>0.05).
Table 20 Pharmaceutical effect of sanguisorba saponins extract (meantS.D., n=10) (mg/kg) 10°) (10/1) (gL) 10°) Coefficient | Contents in
CTI [FE (ng) gow || esos | savas | simi | sense | susan | oomos iotigon || sssen [sean | mass [seas | wos | sss
Low-dose group of | 0.5 2.43+0.22 | 3.09+0.31 126.64+7.43 243.09+£56.22 18.5742.83% | 67.83+5.21%
Sanguisorba a tannins extract
Moderate-dose 1 2.46+0.26 | 3.22+40.28 123.36+11.54 247.65+£38.77 19.8243.03% | 74.95+5.05% group of a
Sanguisorba tannins extract
High-dose group | 2 2.5740.32 | 3.54+0.55 122.96+10.62 254.01£57.52 22.3742.95% | 76.47+7.334 of Sanguisorba a tannins extract
A: P>0.05, compared with the model group
It is generally believed that: Sanguisorba saponins are the active ingredients of sanguisorba for increasing white blood cells and protecting bone marrow;
Sanguisorba saponins also can increase the numbers of white blood cells and platelets in bone marrow inhibition of mice; However, sanguisorba tannins and sanguisorba flavones cannot promote bone marrow cells proliferation, instead cause bone marrow inhibition under high concentrations. During the preparation of sanguisorba extract, it is certainly intended to obtain sanguisorba saponins. However, Inventors unexpectedly and surprisingly find from the above experiments that the active ingredient in sanguisorba for increasing white blood cells is sanguisorba tannins, but not sanguisorba saponins.
Test 6 Influence of Sanguisorba tannins and Sanguisorba saponins on tumor 1 Experimental Materials
C57 mice (half ? and half &, 18-22g, purchased from Institute of Experimental
Animal of Medical Scientific Academy in Sichuan, China); Automatic Blood Cell
Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic
Analytical Balance (BP211D, manufactured by German Sartorius Group);
Cyclophosphamide for Injection; Sanguisorba tannins extract (containing more than 98% of tannins, prepared according to Example 9); and Normal saline.
Lewis lung cancer cell suspension: Mice inoculated with lung cancer cells for 7 days are executed, and ascites are extracted under aseptic condition and centrifuged.
After removing supernate, cancer cells in the lower layer are taken out and diluted into 250mg/ml suspension with normal saline.
Preparation of sanguisorba saponins: The Garden Burnet Root (scientific name:
Radix Sanguisorbae) 1s ground into coarse powders and then reflux extracted with 70% ethanol for 3 times, each for 1.5h. The solution is concentrated to a proper amount (no alcohol flavor) at 70°C under reduced pressure. The concentrate is transferred to a separating funnel, defatted with water-saturated ether twice. The mother liquor is treated at 70°C under reduced pressure to recover the residual ether, then dissolved in water, and extracted twice with water-saturated n-butanol. The extract is then condensed at 80°C under reduced pressure, and solids therein are dissolved through adding ethanol with a certain concentration. The solution is transferred to a beaker, with an appropriate amount of water added to adjust the pH value within the range of 10-14. After standing and being centrifuged, the precipitation is removed. After vacuum drying for 2 hours at 70°C, it is transferred to a triangular flask with a cover, and extracted by ultrasonic through adding anhydrous ethanol. After filtration, the filtrate is condensed at 70°C under reduced pressure to recover ethanol, till to just form precipitation. Then, it is transferred to an evaporation dish, where ethanol is volatilized in a water bath at 80°C. After vacuum drying for 12 hours at 70°C, the residual is taken out and ground. The content of Sanguisorba saponins is 98.18%. 2. Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 60 of C57 mice are randomly divided into 6 groups by weigh, including model group, cyclophosphamide group, sanguisorba tannins extract group, sanguisorba tannins extract + cyclophosphamide group, sanguisorba saponins group, and sanguisorba saponins + cyclophosphamide group (see Table 21 for details). 0.2ml of Lewis lung cancer cell suspension is inoculated in animals of each group by subcutaneous injection through armpits, and modeling is carried out for once. Except for administration to cyclophosphamide group through intraperitoneal injected (ip), animals of each group are administrated as 10g mice weight /0.2ml dosage by intragastric (ig), and the model group is administrated corresponding normal saline for 14 days.
Table 21 Grouping of animals and dosage of drug administration
Growmme | Adminisvatondosage In + Cyclophosphamide group + Cyclophosphamide group 3. Evaluation index and data processing
The animals of each group are executed at 15th day, and the axillary tumors are cut and weighted. The tumor inhibition rate is recorded. Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test a=0.05.
Tumor inhibition rate (%) = {Model group average (tumor weight /body weight)- experiment group average (tumor weight /body weight) }/model group average (tumor weight /body weight)*100%. 4. Result analysis
Table 22 Influence of Sanguisorba tannins and Sanguisorba saponins on tumor /body weight Rate (%)
ModelGrow |. Joss |.
Ee group 0.0758 22.34 rE
Cyclophosphamide group +20mg/kg-d 0.0294 69.88"
Cyclophosphamide group | 20mghkgd
A: P<0.05, compared with Model group
Although it is reported that sanguisorba saponins can be used for anti-tumor, according to the above experiment results, sanguisorba saponins group has no function of tumor inhibition, instead a side effect of stimulating tumor growth.
Moreover, after sanguisorba saponins are used in combination with cyclophosphamide, the tumor inhibition rate is lower than that of cyclophosphamide alone, which indicates that sanguisorba saponins rival the therapy effect of chemical medicines on tumor. However, after using sanguisorba tannins, the therapy effect becomes stronger, and bone marrow cells and whole blood cells are protected also, thus reducing or avoiding the damages to bone marrow cells and whole blood cells caused by chemotherapeutics. Therefore, the content of sanguisorba saponins in the sanguisorba tannins extract of the present invention should be controlled, in order to prevent the side effects of sanguisorba saponins. According to the results of the above examples and tests, the content of total saponins in sanguisorba tannins extract is less than 10% (w/w), and the content of sanguisorbin I is less than 5% (w/w). Preferably, the content of total saponins in sanguisorba tannins extract is less than 0.001% (w/w), and the content of sanguisorbin I is less than 0.0001% (w/w).
Test 7 Pharmaceutical effect of sanguisorba tannins extract of the present invention on bone marrow protection 1. Experimental Materials
KM mice (half # and half &, 18-22¢g, clean grade, Certification No. SCXK (Sichuan) 2004-15, purchased from Institute of Experimental Animal of Medical
Scientific Academy in Sichuan, China); Automatic Blood Cell Counter (MEK-6318, manufactured by Nihon Kohden Corporation); Electronic Analytical Balance (BP211D, manufactured by German Sartorius Group); ELASA; An external ray machine of Co-60 rays; Recombinant human granulocyte-colony stimulating factor (rhG-CSF, 75pg); Normal saline; Sanguisorba tannins extracts of Examples 1-8 (which include 55%-79% (w/w) of tannins and less than 10%(w/w) of sanguisorba saponins). 2. Experimental method 2.1 Grouping and drug administration
The experimental animals used in the present invention are housed in the observation room for animals of Chengdu University of TCM, and maintained under the environment with normal food and water feeding for 3 days before the experiment. 110 mice are randomly divided into 11 groups by gender (see Table 23 for details), prophylactic intragastric (ig) administration of the drug for 3d before modeling. At the 4th day, except for normal group, other groups all are placed in an isolated cycloid plastic box, defining distance based on the box cover as center. A total body irradiation 7.5Gy with Co-60 rays at dose rate of 82.6cGy/min is conducted with the irradiation distance of 80 cm. Except for positive group with chemical drugs, intragastric (ig) administration for 6 days from modeling, and conducting subcutaneous (sc) with rhG-CSF from 7th to 9th day.
Table 23 Grouping and drug administration 2.2 Evaluation index and data processing
Blood is collected from orbits of mice at 7th day after modeling, and detected for parameters of peripheral blood routine by the Automatic Blood Cell Counter, including white blood cell (WBC) count, red blood cell (RBC), Hemoglobin (HGB), and platelet (PLT). Meanwhile, the spleens of mice are taken out and weighted, and the spleen coefficient is calculated. After executing the above treated mice, left-side intact femurs of mice are taken out and the soft tissue thereof are removed. The whole bone marrow is flushed into a test tube with 10ml of 0.005mol/L CaCl. The tube is stood in a fridge at 4°C for 30min, and centrifuged at 2500r/min for 15min. Supernate is removed, and the precipitate is sufficiently mixed with 5ml of 0.2mol/L. HCIOa.
After being heated at 90°C for 15min, the tube is cooled and then centrifuged at 3500r/min for 10min. Supernate is used to determine the OD value at a wavelength of 260nm by ELIASA.
Experimental data are presented as mean+S.D. With SPSS software, statistical test is performed with group t and single factor F, the level of test 0=0.05. 2.3 Result analysis
Table 24 shows the influence of sanguisorba tannins on the bone marrow inhibition caused by Co rays.
Table 24 Comparison on pharmaceutical effect of Sanguisorba tannins prepared by different methods (meantS.D., n=10)
Group Dosage WBC RBC HGB PLT Spleen DNA content (mg/kg) (10°/L) (10/1) (g/L) (10°/L) Coefficient | in bone (mg/10g) | marrow (ug) mcg | [esos | san0n | wnasasss | sons [sion | oases iotigon | [2002 [sw | orsmon | sess | ness [ems group
A: P<0.05, compared with model group
It can be known from the experimental results that the sanguisorba tannins extract of the present invention has a significant protection against the decrease of
DNA content in bone marrow and the decrease of white blood cells caused by chemical substances (P<0.05). Moreover, with the increase of sanguisorba tannins content, the contents of sanguiin, catechins, and proanthocyanidin B2 will increase accordingly, and thus the pharmaceutical effect reflects an upward trend.
Test 8 Side effects of sanguisorba tannins extract 1. Test on acute toxicity
KM mice are randomly divided into a blank group and a drug administration group, 20 animals each group. Normal saline was given to the blank group through intragastric administration, while the largest volume of drug with the highest concentration (around 2g extract /ml) with which animals can endure is given to the animals in the drug administration group through intragastric administration (ig).
Observation for 2 weeks. By calculation, the largest tolerant quantity of mice against the sanguisorba tannins extract (Prepared according to Example 9) is 80g/kg. 2. Test on different drug administration methods
KM mice are randomly divided into an intramuscular injection group, an intragastric administration group, an intraperitoneal group, a subcutaneous injection group and an intravenous administration group, 10 animals each group. Except for the blank group, the equivalent volume of dosage 10mg/kg of sanguisorba tannins extract (Prepared according to Example 9) is added into other groups respectively for 14 days.
After the animals are executed, the histomorphological change of the animals by anatomy are observed and pictured.
Results show other drug administration methods of tannins have strong side effects as follows:
Intraperitoneal (ip): adhesive lesion of muscle or tissue;
Intramuscular injection (im): extravasated blood in muscle;
Subcutaneous injection (sc): congestion in subcutaneous tissues;
Intravenous injection (iv): mice was dead immediately.
However, the method of intragastric (ig) administration proves no side effect, which indicates sanguisorba tannins can be adopted for intragastric administration.
The above experiments on pharmaceutical effect can prove that, the sanguisorba tannins extract of the present invention contains 35%-100%w/w of tannins, less than 10% (w/w) of total saponins, and less than 5% (w/w) of sanguisorbin I. The activity ingredient in the extract is sanguisorba tannins, which has an efficacy increasing with the increase of the content of sanguisorba tannins. Used with the same dosage, high purity sanguisorba tannins are superior to sanguiin and catechins etc., and can protect bone marrow hematopoietic stem cells and have a remarkable protective effect on the inhibition of mice bone marrow DNA caused by chemical substances and radiotherapy and increase the white blood cells. When used in combination with chemotherapeutic drug, sanguisorba tannins can improve the efficacy of anti-tumor, protect bone marrow cells and whole blood cells, reduce or avoid the damages to bone marrow cells and whole blood cells caused by chemotherapeutics. It can be prepared through a simple process with high yield. Therefore, it is a new choice for treating and preventing normal bone marrow cells inhibition caused by radiotherapy and chemotherapy.
The sanguisorba tannins extract of the present invention can protect bone marrow hematopoietic stem cells, and have remarkable protective effects on the inhibition of mice bone marrow DNA caused by chemical substances and radiotherapy. In addition, the sanguisorba tannins extract of the present invention can increase white blood cells significantly. The product provides a new choice for treating and preventing normal bone marrow cells inhibition caused by radiotherapy and chemotherapy with an excellent clinical application and industrial prospects.
Claims (1)
- ClaimsI. A sanguisorba tannins extract, wherein said extract comprises 35%-100% (w/w) of tannins, less than 10% (w/w) of total saponins, and less than 5% (w/w) of sanguisorbin I.2. The extract according to claim 1, wherein said extract contains 50%-100% (w/w) of tannins.3. The extract according to claim 2, wherein said extract contains 55%-100% (w/w) of tannins.4. The extract according to claim 1 or 2, wherein said extract comprises less than7.2% (w/w) of total saponins, and less than 4.9% (w/w) of sanguisorbin I.5. The extract according to claim 4, wherein said extract comprises less than0.001% (w/w) of total saponins, and less than 0.0001% (w/w) of sanguisorbin I.6. The extract according to claim 1 or 2, wherein said sanguisorba tannins comprises 0.05% to 3.0% by weight of sanguiin, 1.0% to 5.0% by weight of catechin, and 0.05% to 1.5% by weight of proanthocyanidin B2, all calculated based on said extract.7. The extract according to claim 6, wherein said sanguisorba tannins comprises1.0% to 2.0% by weight of sanguiin, 2.0% to 4.0% by weight of catechin, and 0.05% to 0.4% by weight of proanthocyanidin B2, all calculated based on said extract.8. The extract according to any one of claims 1 to 7, wherein said extract originates from dried roots of Sanguisorba officinalis I. or Sanguisorba officinalis L.var.longifolia (Bert.) Yu et Li of Rosaceae.9. The extract according to any one of claims 1 to 7, wherein said extract is prepared through the following steps: 1) extraction: grinding Garden Burnet Root into coarse powders, extracting it with water, alcohol, hydrous ethanol, acetone or hydrous acetone, and obtaining a concentrated solution after filtration and concentration ; 2) purification: treating the concentrated solution obtained in step 1) with common tannins separation method, thus obtaining the sanguisorba tannins extract.10. The extract according to claim 9, wherein said common tannins separation method comprises chromatography method, protein precipitation method, solvent method or the combination thereof.11. The extract according to claim 10, wherein in said chromatography method, the absorption is carried out with gel and macro-porous adsorption resin.12. The extract according to claim 10, wherein in said protein precipitation method the precipitation is carried out with gelatin.13. The extract according to claim 10, wherein in said solvent method, aqueous solution containing the concentrated solution is defatted and then extracted by ethyl acetate so as to obtain the sanguisorba tannins extract; alternatively, the concentrated solution is dissolved in ethanol and ethyl acetate, and the extract is precipitated through adding ethyl ether or petroleum ether.14. The extract according to any one of claims 9 to 13, wherein said extract is prepared through the following steps: 1) extraction: grinding Garden Burnet Root into coarse powders, extracting it with water, alcohol, 10%-90% hydrous ethanol, acetone or 50%-90% hydrous acetone, and obtaining a concentrated solution after filtration and concentration; 2) purification: adsorbing and purifying the concentrated solution with macroporous adsorption resin, wherein it is eluted with water into colorless, then with 10% ethanol, finally with 60% ethanol, and collecting the elution with 60% ethanol, thus obtaining the sanguisorba tannins extract after drying; alternatively, defatting the concentrated solution and then extracting it with ethyl acetate, thus obtaining the sanguisorba tannins extract.15. The extract according to claim 14, wherein said macroporous adsorption resin is non-polar resin or low-polar resin.16. The extract according to claim 15, wherein said macroporous adsorption resin is DA-201 macroporous adsorption resin, D-101 macroporous adsorption resin, LSA-20 macroporous adsorption resin, HP-10 macroporous adsorption resin or AB-8 macroporous adsorption resin.17. A process for preparing the extract of claim 1, wherein comprising the following steps: 1) extraction: grinding Garden Burnet Root into coarse powders, extracting it with water, alcohol, hydrous ethanol, acetone or hydrous acetone, and obtaining a concentrated solution after filtration and concentration ; 2) purification: treating the concentrated solution with common tannins separation method, thus obtaining the sanguisorba tannins extract.18. The process according to claim 17, wherein said common tannins separation method comprises chromatography method, protein precipitation method, solvent method or the combination thereof.19. The process according to claim 18, wherein in said chromatography method the absorption is carried out with gel and macro-porous adsorption resin.20. The process according to claim 18, wherein in said protein precipitation method the precipitation is carried out with gelatin.21. The process according to claim 18, wherein in said solvent method, aqueous solution containing the concentrated solution is defatted and then extracted by ethyl acetate so as to obtain the sanguisorba tannins extract; alternatively, the concentrated solution is dissolved in ethanol and ethyl acetate, and the extract is precipitated through adding ethyl ether or petroleum ether.22. The process according to any one of claims 17 to 21, wherein said extract is prepared through the following steps: 1) extraction: grinding Garden Burnet Rootinto coarse powders, extracting it with water, alcohol, 10%-90% hydrous ethanol, acetone or 50%-90% hydrous acetone, and obtaining a concentrated solution after filtration and concentration; 2) purification: adsorbing and purifying the concentrated solution with macroporous adsorption resin, wherein it is eluted with water into colorless, then with 10% ethanol, finally with 60% ethanol, and collecting the elution with 60% ethanol, thus obtaining the sanguisorba tannins extract after drying; alternatively, defatting the concentrated solution and then extracting it with ethyl acetate, thus obtaining the sanguisorba tannins extract.23. The process according to claim 22, wherein said macroporous adsorption resin is DA-201 macroporous adsorption resin, D-101 macroporous adsorption resin,LSA-20 macroporous adsorption resin, HP-10 macroporous adsorption resin or AB-8 macroporous adsorption resin.24. Use of the sanguisorba tannins extract according to any one of claims 1 to 16 for preparing medicaments for protecting bone marrow.25. The use according to claim 24, wherein said medicaments are used to prevent and/or treat bone marrow inhibition.26. The use according to claim 24 or 25, wherein said medicaments are used to prevent and/or treat normal bone marrow cell inhibition caused by radiotherapy or chemotherapy.27. The use according to claim 26, wherein said medicaments are used to prevent and/or treat anemia, leucopenia or thrombocytopenia, preferably leucopenia, caused by radiotherapy or chemotherapy.28. Use of the sanguisorba tannins extract according to any one of claims 1 to 16 for preparing medicaments for the treatment of leucopenia.29. Use of sanguiin and proanthocyanidin B2 for preparing medicaments for protecting bone marrow.30. The use according to claim 29, wherein said medicaments are used to prevent and/or treat bone marrow inhibition.31. The use according to claim 29 or 30, wherein said medicaments are used to prevent and/or treat normal bone marrow cells inhibition caused by radiotherapy or chemotherapy.32. The use according to claim 31, wherein said medicaments are used to prevent and/or treat anemia, leucopenia, or thrombocytopenia, preferably leucopenia, caused by radiotherapy or chemotherapy.33. Use of sanguiin or proanthocyanidin B2 for preparing of medicaments for the treatment of leucopenia.34. A pharmaceutical composition for preventing or treating bone marrow inhibition or leucopenia, wherein comprises an effective amount of sanguiin, proanthocyanidin B2 or the sanguisorba tannins extract according to any one of claims 1-16 as active ingredients, and is prepared to common formulation by adding pharmaceutically acceptable adjuvants or ancillary components.35. The medical composition according to claim 34, wherein said formulation is an oral formulation.36. Use of the sanguisorba tannins extract according to any one of claims 1-16 together with tumor chemotherapeutics for preparing medicaments for the combined treatment of anti-tumor.37. The use according to claim 36, wherein said tumor chemotherapeutics are alkylating agent.38. The use according to claim 37, wherein said tumor chemotherapeutics are cyclophosphamides.39. The use according to claim 36, wherein said medicaments for the combined treatment of anti-tumor is the combined medicaments for the treatment of lung cancer.40. A medical composition for anti-tumor, wherein it is an formulation prepared from an effective amount of tumor chemotherapeutics, the sanguisorba tannins extract according to any one of claims 1-16 as active ingredient, and pharmaceutically acceptable adjuvant.41. The medical composition according to claim 40, wherein said tumor chemotherapeutics are alkylating agent.42. The medicinal composition according to claim 41, wherein said tumor chemotherapeutics are cyclophosphamides.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010280772 | 2010-09-14 | ||
| CN201110186932 | 2011-07-05 | ||
| PCT/CN2011/079633 WO2012034519A1 (en) | 2010-09-14 | 2011-09-14 | Tannin extract of sanguisorba officinalis l. and preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG188529A1 true SG188529A1 (en) | 2013-04-30 |
Family
ID=45831012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505752QA SG10201505752QA (en) | 2010-09-14 | 2011-09-14 | Use of proanthocyanidin b2 for preparing medicaments |
| SG2013018692A SG188529A1 (en) | 2010-09-14 | 2011-09-14 | A sanguisorba tannin extract, and preparation method and use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505752QA SG10201505752QA (en) | 2010-09-14 | 2011-09-14 | Use of proanthocyanidin b2 for preparing medicaments |
Country Status (5)
| Country | Link |
|---|---|
| CN (3) | CN103948710A (en) |
| GB (1) | GB2497899B (en) |
| MY (1) | MY173437A (en) |
| SG (2) | SG10201505752QA (en) |
| WO (1) | WO2012034519A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223036A (en) * | 2013-04-16 | 2013-07-31 | 阚兆云 | Traditional Chinese medicinal composition |
| CN104435220B (en) * | 2013-09-22 | 2018-01-05 | 成都百草和济科技有限公司 | Treat the combination medicine of bone marrow suppression |
| CN104623015A (en) * | 2013-11-08 | 2015-05-20 | 成都百草和济科技有限公司 | New application of garden burnet root and India madder root composition |
| GB201413228D0 (en) | 2014-07-25 | 2014-09-10 | Nugerontix Ltd | Polyphenol compositions |
| CN105147804B (en) * | 2015-08-28 | 2019-04-09 | 四川英路维特医药科技有限公司 | A kind of radix sanguisorbae total saponin extract and its preparation method and application |
| US10155069B2 (en) | 2016-09-09 | 2018-12-18 | King Abdulaziz University | Bone graft with a tannin-hydroxyapatite scaffold and stem cells for bone engineering |
| CN112876523B (en) * | 2021-03-30 | 2023-07-25 | 江西海富生物工程有限公司 | Method for recovering tannic acid from fructus momordicae, sweet tea or stevia rebaudiana floc residues |
| CN114577970B (en) * | 2022-02-18 | 2023-05-12 | 江西普正制药股份有限公司 | Method for establishing blood level tablet fingerprint and fingerprint thereof |
| CN115232516B (en) * | 2022-06-27 | 2023-06-06 | 中南林业科技大学 | Anti-adhesion coating with camellia saponin as main component, preparation method thereof and application thereof in inhibiting bacillus cereus |
| CN115998703B (en) * | 2022-12-14 | 2024-09-06 | 迪沙药业集团有限公司 | Sanguisorba composition and preparation method thereof |
| CN116688012B (en) * | 2023-07-05 | 2024-06-04 | 浙江工业大学 | Buccal tablet for preventing influenza |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58103383A (en) * | 1981-12-12 | 1983-06-20 | Nippon Shinyaku Co Ltd | New tannin |
| JPS58154571A (en) * | 1982-03-08 | 1983-09-14 | Nippon Shinyaku Co Ltd | Novel tannin |
| CN1824631A (en) * | 2005-12-29 | 2006-08-30 | 谢君 | Molecular modification method of active fat soluble plant polyphenol kind substance |
| JP5528025B2 (en) * | 2008-08-22 | 2014-06-25 | 花王株式会社 | TG synthesis inhibitor |
-
2011
- 2011-09-14 CN CN201410032898.0A patent/CN103948710A/en active Pending
- 2011-09-14 SG SG10201505752QA patent/SG10201505752QA/en unknown
- 2011-09-14 CN CN201410032553.5A patent/CN103784434A/en active Pending
- 2011-09-14 GB GB1306569.3A patent/GB2497899B/en active Active
- 2011-09-14 MY MYPI2013000864A patent/MY173437A/en unknown
- 2011-09-14 WO PCT/CN2011/079633 patent/WO2012034519A1/en active Application Filing
- 2011-09-14 CN CN2011800389315A patent/CN103079560A/en active Pending
- 2011-09-14 SG SG2013018692A patent/SG188529A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201306569D0 (en) | 2013-05-22 |
| MY173437A (en) | 2020-01-24 |
| CN103079560A (en) | 2013-05-01 |
| CN103948710A (en) | 2014-07-30 |
| CN103784434A (en) | 2014-05-14 |
| GB2497899B (en) | 2018-05-30 |
| WO2012034519A1 (en) | 2012-03-22 |
| GB2497899A (en) | 2013-06-26 |
| SG10201505752QA (en) | 2015-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG188529A1 (en) | A sanguisorba tannin extract, and preparation method and use thereof | |
| Hu et al. | Flavonoids on diabetic nephropathy: advances and therapeutic opportunities | |
| Goel et al. | Radioprotective potential of an herbal extract of Tinospora cordifolia | |
| Dong et al. | Phytochemicals and biological studies of plants in genus Hedysarum | |
| Tao et al. | Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/NF-κB pathway | |
| Sharma et al. | Berberis lycium Royle fruit extract mitigates oxi-inflammatory stress by suppressing NF-κB/MAPK signalling cascade in activated macrophages and Treg proliferation in splenic lymphocytes | |
| CN115227703B (en) | Application of swertiamarin in preparation of medicine for preventing radioactive intestinal injury | |
| CN103340983B (en) | Lycium ruthenicum fruit extract as well as preparation method and application thereof | |
| CN106389453B (en) | Flavone glycoside composition | |
| CN101863871A (en) | Total glycosides of Rhodiola rosea, medical application and preparation method thereof | |
| Li-Li et al. | Hematopoietic effect of small molecular fraction of Polygoni multiflori Radix Praeparata in cyclophosphamide-induced anemia mice | |
| CN101502585B (en) | Chinese red pepper plant extract as well as preparation method and application thereof | |
| Wang et al. | Whole body radioprotective effect of phenolic extracts from the fruits of Malus baccata (Linn.) Borkh | |
| CN111018821A (en) | Biflavonoid compound and preparation method and application thereof | |
| Xu et al. | Therapeutic effects of combination of paeoniflorin and albiflorin from Paeonia radix on radiation and chemotherapy-induced myelosuppression in mice and rabbits | |
| Ali et al. | Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study | |
| CN104906212B (en) | Raisin tree seed extract and its extraction separation method with hepatoprotective effect and purposes | |
| CN110420247B (en) | Polygonum bulbiferum extract and preparation method and application thereof | |
| CN103816300A (en) | Traditional Chinese medicine pressurized spray for treating skin disorders or mucosa orifice diseases | |
| CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
| Tang et al. | Applying silica gel column chromatography purify resveratrol from extracts of Morus alba L. Leaf | |
| CN102406731B (en) | Combination medicament for preventing or/and treating bone marrow suppression | |
| CN102670670B (en) | Preparation method of ginkgo dipyridolum injection with high content of ginkgo terpene lactones | |
| CN109602759A (en) | The purposes of kusamaki broad-leaved podocarpus seed and receptacle polysaccharide | |
| CN110448651B (en) | Preparation method of Tibetan traditional Chinese medicine composition for treating liver diseases, composition and granules containing composition |